血浆基因分型指导转移性非小细胞肺癌个体化治疗的临床意义
这项前瞻性队列研究纳入323例转移性非小细胞肺癌患者,评估血浆循环肿瘤DNA二代测序(NGS)在常规临床管理中的价值。结果显示,血浆NGS可显著提高可靶向突变检出率并促进分子指导治疗的实施,且基于血浆结果接受靶向治疗的患者缓解率较高。
要点
- 血浆NGS联合组织NGS使可靶向突变检出率从20.5%提升至35.8%。
- 33.0%仅行血浆检测的患者检出可靶向突变,避免了侵入性活检。
- 85.7%基于血浆结果接受靶向治疗的患者达到完全/部分缓解或疾病稳定。
核心结论
- 将血浆NGS整合入IV期NSCLC常规管理可显著提高可靶向突变检出率并改善分子指导治疗的实施。
研究设计与样本
- 前瞻性队列研究,纳入323例在宾夕法尼亚大学医院接受常规临床管理的转移性NSCLC患者,血浆NGS采用73基因商业平台,中位随访7个月(范围1-21个月)。
主要发现
- 113例(35.0%)总体检出EGFR、ALK、MET、BRCA1、ROS1、RET、ERBB2或BRAF可靶向突变。
- 94例(29.1%)仅行血浆检测,其中31例(33.0%)检出可靶向突变,避免了侵入性活检。
- 229例同时行血浆与组织NGS或无法行组织NGS的患者中,组织单独检出可靶向突变47例(20.5%),加血浆检测后增至82例(35.8%)。
- 血浆靶向突变等位基因分数与RECIST缓解深度无相关性(r=-0.121;P=.45)。
临床怎么用
- 对转移性NSCLC患者,在组织NGS基础上加做血浆NGS可提高可靶向突变检出率并指导靶向治疗。
- 当组织活检不可行或患者偏好无创检测时,可优先考虑血浆NGS以筛查可靶向突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The clinical implications of adding plasma-based circulating tumor DNA next-generation sequencing (NGS) to tissue NGS for targetable mutation detection in non-small cell lung cancer (NSCLC) have not been formally assessed. OBJECTIVE: To determine whether plasma NGS testing was associated with improved mutation detection and enhanced delivery of personalized therapy in a real-world clinical setting. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study enrolled 323 patients with metastatic NSCLC who had plasma testing ordered as part of routine clinical management. Plasma NGS was performed using a 73-gene commercial platform. Patients were enrolled at the Hospital of the University of Pennsylvania from April 1, 2016, through January 2, 2018. The database was locked for follow-up and analyses on January 2, 2018, with a median follow-up of 7 months (range, 1-21 months). MAIN OUTCOMES AND MEASURES: The number of patients with targetable alterations detected with plasma and tissue NGS; the association between the allele fractions (AFs) of mutations detected in tissue and plasma; and the association of response rate with the plasma AF of the targeted mutations. RESULTS: Among the 323 patients with NSCLC (60.1% female; median age, 65 years [range, 33-93 years]), therapeutically targetable mutations were detected in EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF for 113 (35.0%) overall. Ninety-four patients (29.1%) had plasma testing only at the discretion of the treating physician or patient preference. Among the 94 patients with plasma testing alone, 31 (33.0%) had a therapeutically targetable mutation detected, thus obviating the need for an invasive biopsy. Among the remaining 229 patients who had concurrent plasma and tissue NGS or were unable to have tissue NGS, a therapeutically targetable mutation was detected in tissue alone for 47 patients (20.5%), whereas the addition of plasma testing increased this number to 82 (35.8%). Thirty-six of 42 patients (85.7%) who received a targeted therapy based on the plasma result achieved a complete or a partial response or stable disease. The plasma-based targeted mutation AF had no correlation with depth of Response Evaluation Criteria in Solid Tumors response (r = -0.121; P = .45). CONCLUSIONS AND RELEVANCE: Integration of plasma NGS testing into the routine management of stage IV NSCLC demonstrates a marked increase of the detection of therapeutically targetable mutations and improved delivery of molecularly guided therapy.
引用
- Aggarwal C, Thompson JC, Black TA, et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019. PMID: 30325992. doi:10.1001/jamaoncol.2018.4305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。